Zhang Yumei, Chen Zhiyu, Li Jin
Department of VIP Clinic, Tongji University South Branch of Shanghai East Hospital Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College Department of Oncology, Tongji University Shanghai East Hospital, Shanghai, China.
Medicine (Baltimore). 2017 Oct;96(40):e8242. doi: 10.1097/MD.0000000000008242.
Colorectal cancer (CRC) is one of the most common cancers all over the world, but its epidemiology is obviously different in various regions.
The treatment of CRC also has varying characteristics due to differences in economy, geography, disease onset, chemotherapy, and other factors, although international guidelines are used to guide the treatment of CRC in China.
This paper summarizes the current status of CRC treatment, including surgical therapy, neoadjuvant radiotherapy and chemotherapy, postoperative chemotherapy, targeted therapy, maintenance therapy, and immunotherapy, according to the clinical situation in China, so as to provide better therapy and improve clinical practice for patients with CRC.
This research shows that the treatment of colorectal cancer continues to progress, and the patient's efficacy and quality of life have improved.
结直肠癌（CRC）是全球最常见的癌症之一，但其流行病学在不同地区存在明显差异。
尽管中国采用国际指南指导结直肠癌的治疗，但由于经济、地理、疾病发病情况、化疗等因素的差异，结直肠癌的治疗也具有不同特点。
本文根据中国的临床情况，总结了结直肠癌治疗的现状，包括手术治疗、新辅助放疗和化疗、术后化疗、靶向治疗、维持治疗和免疫治疗，以便为结直肠癌患者提供更好的治疗并改善临床实践。
本研究表明，结直肠癌的治疗不断进步，患者的疗效和生活质量得到了提高。
